BioGeneration Ventures
Venture Capital
Active
Naarden, Netherlands
51
20M
35
2.83
10
0.31
6
- Stages of investment
- Areas of investment
Summary
In 2006 was created BioGeneration Ventures, which is appeared as VC. The main office of represented VC is situated in the Naarden. The company was established in Europe in The Netherlands.
The top amount of exits for fund were in 2015. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this BioGeneration Ventures performs on 10 percentage points less the average number of lead investments. Considering the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the BioGeneration Ventures, startups are often financed by Thuja Capital, NV NOM, MedSciences Capital. The meaningful sponsors for the fund in investment in the same round are Forbion Capital Partners, New Science Ventures, BOM Capital. In the next rounds fund is usually obtained by Omnes Capital, Forbion Capital Partners, Erasmus MC Biomedical Fund.
Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AcertaPharma, Mellon Medical, Scenic Biotech. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Therapeutics, Health Care. For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands.
Besides them, we counted 5 critical employees of this fund in our database.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- EUR 150000000
- Fund raised date
- 2023-07-13
Analytics
- Total investments
- 51
- Lead investments
- 10
- Exits
- 6
- Rounds per year
- 2.83
- Follow on index
- 0.31
- Investments by industry
- Biotechnology (37)
- Therapeutics (25)
- Health Care (17)
- Medical (16)
- Pharmaceutical (12) Show 18 more
- Investments by region
-
- Netherlands (27)
- United Kingdom (6)
- Germany (3)
- United States (3)
- Belgium (3) Show 2 more
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 123M
- Group Appearance index
- 0.78
- Avg. company exit year
- 4
- Avg. multiplicator
- 32.54
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Panome Bio | 24 Feb 2023 | Early Stage Venture | 6M | United States, St Louis, Missouri | |
| Scenic Biotech | 10 Mar 2022 | Biotechnology, Life Science, Biometrics, Collaborative Consumption | Early Stage Venture | 33M | North Holland, Amsterdam, Netherlands |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.